Steven Cohen Mei Pharma, Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.54 - $2.74 $1.51 Million - $7.67 Million	-2,800,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.33 - $3.37 $3.98 Million - $5.75 Million	1,706,133 Added 155.9%	2,800,500 $7.48 Million
Q3 2021 Nov 15, 2021	BUY	$2.52 - $2.99 $28,622 - $33,960	11,358 Added 1.05%	1,094,367 $3.02 Million
Q2 2021 Aug 16, 2021	SELL	$2.6 - $3.65 $174,696 - $245,247	-67,191 Reduced 5.84%	1,083,009 $3.09 Million
Q1 2021 May 17, 2021	SELL	$2.73 - $4.5 $681,954 - $1.12 Million	-249,800 Reduced 17.84%	1,150,200 $3.95 Million
Q4 2020 Feb 16, 2021	BUY	$2.6 - $3.32 $1.02 Million - $1.3 Million	392,946 Added 39.02%	1,400,000 $3.7 Million
Q3 2020 Nov 16, 2020	SELL	$2.46 - $4.27 $375,681 - $652,097	-152,716 Reduced 13.17%	1,007,054 $3.14 Million
Q2 2020 Aug 14, 2020	BUY	$1.45 - $4.3 $1.68 Million - $4.99 Million	1,159,770 New	1,159,770 $4.79 Million
Q1 2020 May 15, 2020	SELL	$0.75 - $2.55 $637,500 - $2.17 Million	-850,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.65 - $2.48 $1.4 Million - $2.11 Million	850,000 New	850,000 $2.11 Million

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $380M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.